1. Home
  2. SPT vs MYGN Comparison

SPT vs MYGN Comparison

Compare SPT & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SPT

Sprout Social Inc

HOLD

Current Price

$8.44

Market Cap

485.7M

Sector

Technology

ML Signal

HOLD

Logo Myriad Genetics Inc.

MYGN

Myriad Genetics Inc.

HOLD

Current Price

$2.91

Market Cap

444.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPT
MYGN
Founded
2010
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
485.7M
444.2M
IPO Year
2019
1996

Fundamental Metrics

Financial Performance
Metric
SPT
MYGN
Price
$8.44
$2.91
Analyst Decision
Buy
Buy
Analyst Count
8
7
Target Price
$11.75
$7.64
AVG Volume (30 Days)
925.9K
978.5K
Earning Date
05-07-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
32.11
N/A
EPS
N/A
N/A
Revenue
$457,547,000.00
$771,400,000.00
Revenue This Year
$8.86
$6.86
Revenue Next Year
$8.04
$5.45
P/E Ratio
N/A
N/A
Revenue Growth
12.72
2.33
52 Week Low
$4.92
$3.53
52 Week High
$16.03
$8.59

Technical Indicators

Market Signals
Indicator
SPT
MYGN
Relative Strength Index (RSI) 55.28 23.12
Support Level $7.47 N/A
Resistance Level $9.12 $5.17
Average True Range (ATR) 0.48 0.31
MACD -0.01 -0.26
Stochastic Oscillator 60.10 5.30

Price Performance

Historical Comparison
SPT
MYGN

About SPT Sprout Social Inc

Sprout Social Inc develops a cloud software that brings together social messaging, data and workflows in a unified system of record, intelligence, and action. It has a centralized, secure and powerful platform that can scale horizontally across an organization to drive maximum business value. The firm generates majority revenue from software subscriptions. Geographically, the company operates in Americas, EMEA, and Asia Pacific, of which it derives maximum revenue from Americas.

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

Share on Social Networks: